Cross-Sector entity
All 1 tracked stories fall under one category: pharma. ASEAN is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Cross-Sector story that mention Budi Gunadi Sadikin, all published on July 13, 2026.
1 verified story tracked
Last mentioned: Jul 13, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. ASEAN is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. We currently track 1 Cross-Sector story that mention Budi Gunadi Sadikin, all published on July 13, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Budi Gunadi Sadikin. Shared-story counts are live from our verified record — not editorial picks.
Takeda receives Indonesia’s first plasma fractionation license, part of a $30 million collaboration to build a domestic plasma ecosystem. The initiative aims to scale manufacturing of plasma-derived medicinal products, positioning Indonesia as a regional biopharma hub.
Source: Business Wire (ca) · Business Wire (ca)
